1. WHO, Regional Office for Europe. Guidance on conducting serosurveys in support of measles and rubella elimination in the WHO European Region. 2013.
  2. Dimech W, Mulder MN. A review of testing used in seroprevalence studies on measles and rubella. Vaccine, 2016, 34:4119-4122.
  3. Vyse AJ et al. Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiology and Infection, 2006, 134: 1303-1312.
  4. Ward BJ et al. Cellular immunity in measles vaccine failure: Demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. Journal of Infectious Diseases, 1995, 172:1591-1595.
  5. Skendzel LP. Rubella immunity. Defining the level of protective antibody. American Journal of Clinical Pathology, 1996, 106:170-174.
  6. WHO. Correlates of vaccine-induced protection: methods and implications. 2013. https://apps.who.int/iris/rest/bitstreams/299888/retrieve
  7. Tischer A et al. Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests. Journal of Clinical Virology, 2007, 38:204-209.
  8. Dorigo-Zetsma JW et al. Immune status of health care workers to measles virus: evaluation of protective titers in four measles IgG EIAs. Journal of Clinical Virology, 2015, 69:214-218.
  9. Itoh M et al. Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups. Journal of Clinical Microbiology, 2002, 40:1733-1738.
  10. Dimech W. Standardization of assays that detect anti-rubella rirus IgG antibodies. Clinical Microbiology Reviews, 2016, 29:163-174.
  11. Bouthry E et al. Assessing immunity to rubella virus: a plea for standardization of IgG (immuno)assays. Journal of Clinical Microbiology, 2016, 54(7):1720-1725.
  12. Tischer A et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiology and Infection, 2007, 135:787-797.
  13. Andrews N et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bulletin of the World Health Organization, 2008, 86(3):197-204.
  14. Dimech W et al. Investigation into low-level anti-rubella virus IgG results reported by commercial immunoassays. Clinical Vaccine Immunology, 2013, 20:255-261.
  15. Albrecht P et al. Role of virus strain in conventional and enhanced measles plaque neutralization test. Journal of Virological Methods, 1981, 3:251-260.
  16. Chen RT et al. Measles antibody: reevaluation of protective titers. Journal of Infectious Diseases, 1990, 162: 1036-1042.
  17. Cohen BJ et al. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine, 2007, 26:59-66.
  18. Cohen BJ et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. Journal of Virological Methods, 2006, 131:209-212.
  19. de Swart RL et al. Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. Journal of Virology, 2005, 79(17):11547-11551.
  20. Smits GP et al. Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus. Clinical Vaccine Immunology, 2012, 19:396-400.
  21. Lambert ND. High-throughput assay optimization and statistical interpolation of rubella-specific neutralizing antibody titers. Clinical Vaccine Immunology, 2014, 21:340-346.